{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T20:33:00Z","timestamp":1785443580234,"version":"3.56.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"46","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.vaccine.2023.09.062","type":"journal-article","created":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T03:13:15Z","timestamp":1696648395000},"page":"6802-6809","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Thrombosis with thrombocytopenia syndrome (TTS) following adenovirus vector COVID-19 vaccination in Canada"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6971-2794","authenticated-orcid":false,"given":"T.D.","family":"Procter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7531-264X","authenticated-orcid":false,"given":"H.","family":"Ogasawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7355-3518","authenticated-orcid":false,"given":"S.","family":"Spruin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1745-1022","authenticated-orcid":false,"given":"S.","family":"Wijayasri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8634-4415","authenticated-orcid":false,"given":"N.","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6565-1742","authenticated-orcid":false,"given":"C.","family":"Blaser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Hutchings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ogunnaike-Cooke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.09.062_b0005","unstructured":"Government of Canada. Health Canada authorizes AstraZeneca and Verity Pharmaceuticals Inc.\/Serum Institute of India COVID-19 vaccines. 2021;2022(May 26)."},{"key":"10.1016\/j.vaccine.2023.09.062_b0010","unstructured":"European Medicines Agency. Vaxzevria (previously COIVD-19 Vaccine AstraZeneca). ;2022(May 27)."},{"key":"10.1016\/j.vaccine.2023.09.062_b0015","unstructured":"Government of Canada. Health Canada authorizes Janssen COVID-19 vaccine. 2021;2022(June 1)."},{"key":"10.1016\/j.vaccine.2023.09.062_b0020","unstructured":"U.S. Food & Drug Administration. FDA Issues Emergency Use Authorization for Thrid COVID-19 Vaccine. 2021;2022(May 30)."},{"key":"10.1016\/j.vaccine.2023.09.062_b0025","unstructured":"European Medicines Agency. COVID-19 Vaccine AstraZeneca: PRAC investigating cases of thromboembolic events- vaccine's benefits currently still outweigh risks- Update. 2021;2023(August 20,)."},{"key":"10.1016\/j.vaccine.2023.09.062_b0030","unstructured":"European Medicines Agency. COVID-19 Vaccine AstraZeneca: PRAC preliminary view suggests no specific issue with batch used in Austria. 2021;2023(August 20,)."},{"issue":"22","key":"10.1016\/j.vaccine.2023.09.062_b0035","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.vaccine.2023.09.062_b0040","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1056\/NEJMc2105869","article-title":"Thrombotic thrombocytopenia after Ad26.COV2.S vaccination","volume":"384","author":"Muir","year":"2021","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.vaccine.2023.09.062_b0045","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1056\/NEJMc2106075","article-title":"Thrombotic thrombocytopenia after Ad26.COV2.S Vaccination \u2014 response from the manufacturer","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.vaccine.2023.09.062_b0050","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMoa2105385","article-title":"Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Scully","year":"2021","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.vaccine.2023.09.062_b0055","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.09.062_b0060","doi-asserted-by":"crossref","unstructured":"See I, Lale A, Marquez P, Streiff MB, Wheeler AP, Tepper NK et al. Case series of thrombosis with thrombocytopenia syndrome following COVID-19 vaccination\u2014United States, December 2020\u2013August 2021. medRxiv 2021:2021.11.10.21266063.","DOI":"10.1101\/2021.11.10.21266063"},{"issue":"10","key":"10.1016\/j.vaccine.2023.09.062_b0065","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/jth.13066","article-title":"Distinguishing between anti-platelet factor 4\/heparin antibodies that can and cannot cause heparin-induced thrombocytopenia","volume":"13","author":"Nazi","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"7873","key":"10.1016\/j.vaccine.2023.09.062_b0070","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41586-021-03744-4","article-title":"Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia","volume":"596","author":"Huynh","year":"2021","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.vaccine.2023.09.062_b0075","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1182\/bloodadvances.2022007766","article-title":"The clinical and laboratory diagnosis of vaccine-induced immune thrombotic thrombocytopenia","volume":"6","author":"Bissola","year":"2022","journal-title":"Blood Adv"},{"issue":"34","key":"10.1016\/j.vaccine.2023.09.062_b0080","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1016\/j.vaccine.2021.07.013","article-title":"Thrombosis with thrombocytopenia syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination \u2013 a risk\u2013benefit analysis for people < 60 years in Australia","volume":"39","author":"MacIntyre","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.09.062_b0085","unstructured":"Government of the United Kingdom. Coronavirus vaccine-weekly summary of Yellow Card reporting. 2022;2022(May 30)."},{"key":"10.1016\/j.vaccine.2023.09.062_b0090","unstructured":"European Medicines Agency. COVID-19 vaccine saftey update Vaxzevria AstraZeneca AB. 2021;2022(May 30)."},{"issue":"4","key":"10.1016\/j.vaccine.2023.09.062_b0095","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1182\/blood.2021012152","article-title":"Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know","volume":"138","author":"Arepally","year":"2021","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.vaccine.2023.09.062_b0100","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMoa2109908","article-title":"Clinical features of vaccine-induced immune thrombocytopenia and thrombosis","volume":"385","author":"Pavord","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.09.062_b0105","unstructured":"Chen RT, Buttery Monash J. Interim case definition of thrombosis with thrombocytopenia syndrome (TTS). 2021."},{"key":"10.1016\/j.vaccine.2023.09.062_b0110","unstructured":"Canadian case definition for thrombosis with thrombocytopenia syndrome (TTS). 2021."},{"key":"10.1016\/j.vaccine.2023.09.062_b0115","unstructured":"Public Health Agency of Canada. Canadian Adverse Events Following Immunization Surveillance System (CAEFISS). 2022;2022(May 26)."},{"key":"10.1016\/j.vaccine.2023.09.062_b0120","unstructured":"Health Canada. Canada Vigilance Adverse Reaction Online Database. 2022;2022(May 26)."},{"key":"10.1016\/j.vaccine.2023.09.062_b0125","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. MedDRA Medical Dictionary for Regulatory Activities. ;2022(October 31)."},{"issue":"8","key":"10.1016\/j.vaccine.2023.09.062_b0130","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa2107051","article-title":"Adjunct immune globulin for vaccine-induced immune thrombotic thrombocytopenia","volume":"385","author":"Bourguignon","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2023.09.062_b0135","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood.V67.1.27.27","article-title":"A diagnostic test for heparin-induced thrombocytopenia","volume":"67","author":"Sheridan","year":"1986","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.vaccine.2023.09.062_b0140","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/09537104.2017.1378808","article-title":"Development of a high-yield expression and purification system for platelet factor 4","volume":"29","author":"Huynh","year":"2018","journal-title":"Platelets"},{"key":"10.1016\/j.vaccine.2023.09.062_b0145","unstructured":"Public Health Agency of Canada. COVID-19 vaccination coverage surveillance system (CCVCSS). 2021."},{"key":"10.1016\/j.vaccine.2023.09.062_b0150","unstructured":"Canadian Institute for Health Information. Discharge Abstract Database, fiscal years 2014\u20132020."},{"key":"10.1016\/j.vaccine.2023.09.062_b0155","unstructured":"Canadian Institute for Health Information. National Ambulatory Care Reporting System, fiscal years 2014\u20132020."},{"key":"10.1016\/j.vaccine.2023.09.062_b0160","unstructured":"Statistics Canada Centre for Demography. Statistics Canada population estimates, 2015\u20132019."},{"key":"10.1016\/j.vaccine.2023.09.062_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2022.05.048","article-title":"Myocarditis and\/or pericarditis risk after mRNA COVID-19 vaccination: a Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines","author":"Abraham","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.09.062_b0170","unstructured":"Silva IR, Kulldorff M. Exact Sequential Analysis for Poisson and Binomial Data (R package). 2022."},{"key":"10.1016\/j.vaccine.2023.09.062_b0175","doi-asserted-by":"crossref","unstructured":"Kulldorff M, Davis RL, Kolczak\u2020 M, Lewis E, Lieu T, Platt R. A Maximized Sequential Probability Ratio Test for Drug and Vaccine Safety Surveillance. 2011;30(1):58\u201378.","DOI":"10.1080\/07474946.2011.539924"},{"issue":"3","key":"10.1016\/j.vaccine.2023.09.062_b0180","first-page":"373","article-title":"Continuous post-market sequential safety surveillance with minimum events to signal","volume":"15","author":"Kulldorff","year":"2017","journal-title":"Revstat Stat J"},{"issue":"2","key":"10.1016\/j.vaccine.2023.09.062_b0185","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s11009-017-9586-z","article-title":"Error probability spending for post-market drug and vaccine safety surveillance with poisson data","volume":"20","author":"Silva","year":"2018","journal-title":"Methodol Comput Appl Probab"},{"issue":"22","key":"10.1016\/j.vaccine.2023.09.062_b0190","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1002\/sim.9094","article-title":"Exact sequential test for clinical trials and post-market drug and vaccine safety surveillance with Poisson and binary data","volume":"40","author":"Silva","year":"2021","journal-title":"Stat Med"},{"issue":"10300","key":"10.1016\/j.vaccine.2023.09.062_b0195","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0140-6736(21)01693-7","article-title":"Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis","volume":"398","author":"Bhuyan","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.09.062_b0200","unstructured":"Government of Canada. Adverse events in Europe following immunization with the AstraZeneca COVID-19 vaccine. 2021;2023(April 13)."},{"key":"10.1016\/j.vaccine.2023.09.062_b0205","unstructured":"Government of Canada. Health Canada provides update on safety review of AstraZeneca and COVISHIELD COVID-19 vaccines. 2021;2022(September 20)."},{"key":"10.1016\/j.vaccine.2023.09.062_b0210","unstructured":"Government of Canada. Health Canada confirms that the benefits of the AstraZeneca COVID-19 vaccine continue to outweigh the risks for use in Canada. 2021;2023(April 13)."},{"key":"10.1016\/j.vaccine.2023.09.062_b0215","unstructured":"Government of Canada. Health Canada issues label change and guidance on the AstraZeneca COVID-19 vaccine. 2021;2022(September 20)."},{"key":"10.1016\/j.vaccine.2023.09.062_b0220","unstructured":"Verity Pharmaceuticals I. COVISHEILD Product Monograph. 2021."},{"key":"10.1016\/j.vaccine.2023.09.062_b0225","unstructured":"AstraZeneca Canada Inc. Vaxzevria Product Monograph. 2022."},{"key":"10.1016\/j.vaccine.2023.09.062_b0230","unstructured":"Government of Canada. Archived 7: National Advisory Committee on Immunization: Summary of updated vaccine statement of April 23, 2021. 2021;2022(September 20)."},{"key":"10.1016\/j.vaccine.2023.09.062_b0235","unstructured":"Government of Canada. Archived 8: NACI rapid response: Recommended use of AstraZeneca COVID-19 vaccine in younger adults[2021-03-29]. 2021;2022(September 20)."},{"key":"10.1016\/j.vaccine.2023.09.062_b0240","unstructured":"Government of Canada. Archived 14: Summary of National Advisory Committee on Immunization statement of June 17, 2021. 2021;2022(September 20)."},{"key":"10.1016\/j.vaccine.2023.09.062_b0245","unstructured":"Government of Canada. Canadian COVID-19 vaccination safety report. 2022;2022(October 3)."},{"key":"10.1016\/j.vaccine.2023.09.062_b0250","unstructured":"Government of Canada. Use of AstraZeneca COVID-19 vaccine in younger adults. 2021;2022(September 20)."},{"key":"10.1016\/j.vaccine.2023.09.062_b0255","unstructured":"Public Health Agency of Canada, Thrombosis Canada, National Collaborating Centre for Infectious Diseases. COVID-19 Vaccine Energing Issues: Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT). 2021;2023(April 13)."},{"key":"10.1016\/j.vaccine.2023.09.062_b0260","unstructured":"Government of Canada. Thrombosis with thrombocytopenia syndrome: Findings from the Advisory Committee on Causality Assessment. 2023;2023(April 13)."},{"key":"10.1016\/j.vaccine.2023.09.062_b0265","unstructured":"Government of Canada. Advisory Committee on Causality Assessment. 2023;2023(February 1)."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23011593?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23011593?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:31:23Z","timestamp":1759404683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23011593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":53,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0264410X23011593"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.09.062","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombosis with thrombocytopenia syndrome (TTS) following adenovirus vector COVID-19 vaccination in Canada","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.09.062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}